Published in Z Rheumatol on December 01, 2010
Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity (1995) 10.65
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum (2008) 9.94
Length of life and cause of death in rheumatoid arthritis. N Engl J Med (1953) 7.62
Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis (2004) 6.45
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum (2003) 5.29
Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum (2002) 4.69
Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum (2005) 4.64
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2006) 4.20
TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol (2002) 3.96
Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA (2009) 3.90
Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) (2003) 3.70
Predictors of infection in rheumatoid arthritis. Arthritis Rheum (2002) 3.47
Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) (2005) 3.42
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum (2007) 3.38
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol (2009) 3.26
Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum (2006) 3.26
Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med (2010) 3.16
Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum (2006) 3.16
Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum (2004) 3.06
BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax (2005) 3.06
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum (2009) 2.92
Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med (2001) 2.81
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis (2009) 2.65
The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol (2008) 2.60
Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum (2003) 2.57
Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) (2007) 2.55
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum (2006) 2.54
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis (2007) 2.53
Retracted Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol (2010) 2.49
General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2006) 2.47
Reactivation of hepatitis B. Hepatology (2009) 2.46
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum (2007) 2.46
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum (2005) 2.45
Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) (2006) 2.43
Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis (1990) 2.42
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis (2010) 2.40
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.37
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum (2005) 2.35
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum (2004) 2.35
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis (2008) 2.33
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum (2006) 2.28
Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum (1998) 2.19
The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum (2007) 2.16
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum (2002) 2.12
Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol (2004) 2.07
Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol (2009) 2.03
Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut (2004) 2.03
Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep (2000) 1.91
Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis (2005) 1.88
Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis (2010) 1.87
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis (2007) 1.83
Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum (2007) 1.80
Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol (2002) 1.77
Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum (2010) 1.73
Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc (2001) 1.70
Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis (2009) 1.70
Recommended adult immunization schedule: United States, 2009*. Ann Intern Med (2009) 1.69
Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis (2004) 1.68
Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists. J Rheumatol (2010) 1.63
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis (2010) 1.63
Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis (2005) 1.59
Can immunization precipitate connective tissue disease? Report of five cases of systemic lupus erythematosus and review of the literature. Semin Arthritis Rheum (1999) 1.59
Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum (2003) 1.58
[Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases]. Z Rheumatol (2009) 1.58
Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers. Q J Med (1989) 1.57
Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis (2008) 1.56
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis (2006) 1.56
Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum (2002) 1.51
Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis (2006) 1.48
Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med (2003) 1.47
Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis (1994) 1.47
Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) (2005) 1.46
Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol (2007) 1.41
Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol (2003) 1.41
Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) (2006) 1.40
Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis (2007) 1.37
Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol (2007) 1.37
Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis (2001) 1.35
Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis (2003) 1.35
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum (2009) 1.33
Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum (2010) 1.27
Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al. Arthritis Res Ther (2006) 1.27
Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum (2006) 1.26
Influenza immunization in systemic lupus eruthematosus. A double-blind trial. Ann Intern Med (1978) 1.26
Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum (2004) 1.25
Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis (2008) 1.25
Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med (2006) 1.23
Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int (2010) 1.22
Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther (2007) 1.22
Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) (2006) 1.22
Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases. Clin Infect Dis (2006) 1.22
Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis (2004) 1.20
Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood (2003) 1.19
Inhibitors of protein synthesis and RNA synthesis prevent neuronal death caused by nerve growth factor deprivation. J Cell Biol (1988) 4.06
Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity (1996) 2.96
Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest (1985) 2.77
Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med (2001) 2.56
Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature (1985) 2.51
Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS (1999) 2.47
The IgG Fc receptor family. Ann Hematol (1998) 2.28
CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol (2001) 2.13
Mice conditionally lacking the Wolfram gene in pancreatic islet beta cells exhibit diabetes as a result of enhanced endoplasmic reticulum stress and apoptosis. Diabetologia (2005) 2.08
Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones. Science (1985) 1.83
Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol (1991) 1.68
Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology (Oxford) (2000) 1.64
A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med (1986) 1.63
Activation of CD16+ effector cells by rheumatoid factor complex. Role of natural killer cells in rheumatoid arthritis. Arthritis Rheum (1991) 1.56
Bone marrow-derived elements in the peripheral nervous system. An immunohistochemical and ultrastructural investigation in chimeric rats. Lab Invest (1993) 1.53
Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). J Immunol (1998) 1.49
A mass in the eye. Lancet (2002) 1.46
Chronic headache resulting from postoperative supraorbital neuralgia. Anesth Analg (1991) 1.45
Biology of GPI anchors and pathogenesis of paroxysmal nocturnal hemoglobinuria. Immunol Today (1994) 1.43
Towards a better definition of human leucocyte surface molecules. Immunol Today (1989) 1.42
FcgammaRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. Blood (1998) 1.40
Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases. Clin Nephrol (1993) 1.40
Proteoglycans in cell-mediated cytotoxicity. Identification, localization, and exocytosis of a chondroitin sulfate proteoglycan from human cloned natural killer cells during target cell lysis. J Exp Med (1985) 1.37
The two soluble forms of the lipopolysaccharide receptor, CD14: characterization and release by normal human monocytes. Eur J Immunol (1994) 1.36
Association of multiple sclerosis with ILT6 deficiency. Genes Immun (2005) 1.34
Decreased expression and activity of G-protein-coupled receptor kinases in peripheral blood mononuclear cells of patients with rheumatoid arthritis. FASEB J (1999) 1.33
Characterization of functional surface structures on human natural killer cells. Adv Immunol (1988) 1.30
Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum (2004) 1.29
GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients? J Infect Dis (1998) 1.27
Specific release of proteoglycans from human natural killer cells during target lysis. Nature (1985) 1.26
Acute systemic reaction and lung alterations induced by an antiplatelet integrin gpIIb/IIIa antibody in mice. Blood (1999) 1.25
Biosynthesis of glycosylphosphatidylinositols in mammals and unicellular microbes. Biol Chem (1999) 1.25
Distinct tissue site-specific requirements of mast cells and complement components C3/C5a receptor in IgG immune complex-induced injury of skin and lung. J Immunol (2001) 1.24
Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol (1997) 1.24
Functional characterization of LFA-1 antigens in the interaction of human NK clones and target cells. J Immunol (1985) 1.22
CD16- CD56+ natural killer cells after bone marrow transplantation. Blood (1992) 1.21
Time kinetics of the endocrine response to acute psychological stress. J Clin Endocrinol Metab (1996) 1.19
The glycosylphosphatidylinositol-linked Fc gamma receptor III represents the dominant receptor structure for immune complex activation of neutrophils. Eur J Immunol (1992) 1.18
Changes of natural killer cells during acute psychological stress. J Clin Immunol (1993) 1.18
Affected paroxysmal nocturnal hemoglobinuria T lymphocytes harbor a common defect in assembly of N-acetyl-D-glucosamine inositol phospholipid corresponding to that in class A Thy-1- murine lymphoma mutants. J Biol Chem (1992) 1.17
Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol (1993) 1.17
A codominant role of Fc gamma RI/III and C5aR in the reverse Arthus reaction. J Immunol (2000) 1.17
Biochemical changes after trauma and skeletal surgery of the lower extremity: quantification of the operative burden. Crit Care Med (2000) 1.16
Simultaneous detection of TDT-mediated dUTP-biotin nick end-labeling (TUNEL)-positive cells and multiple immunohistochemical markers in single tissue sections. Biotechniques (1995) 1.16
Role of nerve growth factor in the adult dorsal root ganglia neuron and its response to injury. J Comp Neurol (1984) 1.14
Chloroquine-induced neuronal cell death is p53 and Bcl-2 family-dependent but caspase-independent. J Neuropathol Exp Neurol (2001) 1.14
Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol (1998) 1.13
Function of the LFA-1 and T4 molecules in the direct activation of resting human B lymphocytes by T lymphocytes. Eur J Immunol (1986) 1.12
Adjuvant arthritis induces down-regulation of G protein-coupled receptor kinases in the immune system. J Immunol (2001) 1.12
Recurrent, multifocal Mycobacterium avium-intercellulare infection in a patient with interferon-gamma autoantibody. Clin Infect Dis (2009) 1.11
Characteristics and uses of natural killer cells. Immunol Today (1988) 1.09
Opposed independent effects and epistasis in the complex association of IRF5 to SLE. Genes Immun (2007) 1.08
The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for ligand binding. J Immunol (1996) 1.08
Nerve growth factor regulates sympathetic ganglion cell morphology and survival in the adult mouse. J Neurosci (1990) 1.07
Fc gamma RIII-mediated production of TNF-alpha induces immune complex alveolitis independently of CXC chemokine generation. J Immunol (2001) 1.06
Intrinsic human glomerular mesangial cells can express receptors for IgG complexes (hFc gamma RIII-A) and the associated Fc epsilon RI gamma-chain. J Immunol (1994) 1.05
Enhancement of natural killer function through activation of the T11 E rosette receptor. J Clin Invest (1987) 1.05
Expression of the NKTa clonotype in a series of human natural killer clones with identical cytotoxic specificity. J Exp Med (1986) 1.04
Mouse FcgammaRII is a negative regulator of FcgammaRIII in IgG immune complex-triggered inflammation but not in autoantibody-induced hemolysis. Eur J Immunol (2000) 1.04
Systemic pathology of chimpanzees. J Med Primatol (1975) 1.04
Bias in association studies of systemic lupus erythematosus susceptibility due to geographical variation in the frequency of a programmed cell death 1 polymorphism across Europe. Genes Immun (2007) 1.04
High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura. Lancet (1981) 1.02
The role of interleukin 2 and T11 E rosette antigen in activation and proliferation of human NK clones. J Immunol (1985) 1.02
Development of the glycosylphosphatitylinositol-anchoring defect characteristic for paroxysmal nocturnal hemoglobinuria in patients with aplastic anemia. Blood (1994) 1.02
Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol (2006) 1.02
Positional support for premature infants. Am J Occup Ther (1986) 1.02
Diagnosis of paroxysmal nocturnal haemoglobinuria using immunophenotyping of peripheral blood cells. Br J Haematol (1991) 1.02
Cutting edge: Fc receptor type I for IgG on macrophages and complement mediate the inflammatory response in immune complex peritonitis. J Immunol (1999) 1.01
Mycobacterium genavense. Autopsy findings in three patients. Am J Clin Pathol (1994) 1.01
Experimental diabetic autonomic neuropathy. Am J Pathol (1981) 1.01
Lack of specific receptors for C-reactive protein on white blood cells. Eur J Immunol (2001) 1.00
IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis. SLE Study Group. Rheumatol Int (1998) 1.00
CD antigens 1989. Blood (1989) 0.99
In vitro regulation of human hematopoiesis by natural killer cells: analysis at a clonal level. Blood (1987) 0.98
Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors. AIDS (1999) 0.98
The IgG binding site of human FcgammaRIIIB receptor involves CC' and FG loops of the membrane-proximal domain. J Biol Chem (1996) 0.97
The high-affinity Fc gamma RI on PMN: regulation of expression and signal transduction. Immunology (1997) 0.97
Association of immunoglobulin-like transcript 6 deficiency with Sjögren's syndrome. Arthritis Rheum (2009) 0.97
Catecholamines modulate human NK cell circulation and function via spleen-independent beta 2-adrenergic mechanisms. J Immunol (1996) 0.96
Fast and slow axoplasmic flow in sciatic nerve of diabetic rats. Diabetes (1975) 0.96
Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis (2012) 0.95
Retrograde axonal transport of intravenously administered 125I-nerve growth factor in rats with streptozotocin-induced diabetes. Diabetes (1983) 0.95
Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf (2000) 0.95
Nutrition counseling--should physicians guide their patients? Am J Prev Med (1995) 0.94
Modulation of the immunologic response to acute stress in humans by beta-blockade or benzodiazepines. FASEB J (1996) 0.94
Beta-endorphin, but not substance-P, is increased by acute stress in humans. Psychoneuroendocrinology (1995) 0.94
Reduction malformations and chromosome anomalies. Am J Dis Child (1973) 0.93
Activation of cloned human natural killer cells via Fc gamma RIII. J Immunol (1989) 0.93
Experimental diabetic autonomic neuropathy characterization in streptozotocin-diabetic Sprague-Dawley rats. Lab Invest (1983) 0.93
Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. Eur J Med Res (2002) 0.93
CD8beta/CD28 expression defines functionally distinct populations of peripheral blood T lymphocytes. Clin Exp Immunol (2003) 0.93
Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32). Ann Rheum Dis (2007) 0.92
Transitional cell carcinoma metastatic to the eye of a dog. Vet Pathol (1981) 0.92
Catecholamines induce alterations of distribution and activity of human natural killer (NK) cells. J Clin Immunol (1993) 0.92
Enhanced frequency of a PTPRC (CD45) exon A mutation (77C-->G) in systemic sclerosis. Genes Immun (2003) 0.91
IFN-gamma induces the high-affinity Fc receptor I for IgG (CD64) on human glomerular mesangial cells. Eur J Immunol (1998) 0.91
IgA and IgG autoantibodies against alpha-fodrin as markers for Sjögren's syndrome. Systemic lupus erythematosus. J Rheumatol (2000) 0.91
Primary myopathy and accumulation of PrPSc-like molecules in peripheral tissues of transgenic mice expressing a prion protein insertional mutation. Neurobiol Dis (2001) 0.91